NASDAQ:ANNX - Annexon Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.33
  • Forecasted Upside: 57.64 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$21.78
▲ +0.26 (1.21%)
1 month | 3 months | 12 months
Get New Annexon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANNX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.33
▲ +57.64% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Annexon in the last 3 months. The average price target is $34.33, with a high forecast of $37.00 and a low forecast of $33.00. The average price target represents a 57.64% upside from the last price of $21.78.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Annexon.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2021Needham & Company LLCInitiated CoverageBuy$37.00Medium
i
9/1/2020Robert W. BairdInitiated CoverageOutperformHigh
i
8/18/2020JPMorgan Chase & Co.Initiated CoverageOverweight$33.00Low
i
8/18/2020Bank of AmericaInitiated CoverageBuy$33.00 ➝ $33.00High
i
8/18/2020CowenInitiated CoverageOutperformHigh
i
(Data available from 4/21/2016 forward)
Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, engages in developing therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its products in pipelines are focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. Its products include ANX005 (IV), which is in Phase III stage with guillain-barré syndrome indication, as well as in Phase II stage with warm autoimmune hemolytic anemia, huntington's disease, and amyotrophic lateral sclerosis indications; ANX007 (IVT), a Phase II candidate with geographic atrophy indication; and ANX009 (SubQ), which is in Phase I stage with autoimmune indications. The company was founded in 2011 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $21.78
$21.36
$22.34

50 Day Range

MA: $28.28
$21.52
$35.01

52 Week Range

Now: $21.78
$15.33
$38.01

Volume

68,438 shs

Average Volume

161,113 shs

Market Capitalization

$831.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Annexon?

The following equities research analysts have issued reports on Annexon in the last year: Bank of America Co., Cowen Inc, JPMorgan Chase & Co., Needham & Company LLC, Robert W. Baird, and Zacks Investment Research.
View the latest analyst ratings for ANNX.

What is the current price target for Annexon?

3 Wall Street analysts have set twelve-month price targets for Annexon in the last year. Their average twelve-month price target is $34.33, suggesting a possible upside of 57.6%. Needham & Company LLC has the highest price target set, predicting ANNX will reach $37.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $33.00 for Annexon in the next year.
View the latest price targets for ANNX.

What is the current consensus analyst rating for Annexon?

Annexon currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ANNX will outperform the market and that investors should add to their positions of Annexon.
View the latest ratings for ANNX.

What other companies compete with Annexon?

How do I contact Annexon's investor relations team?

The company's listed phone number is 650 822 5500 and its investor relations email address is [email protected] The official website for Annexon is www.annexonbio.com.